Asset Management One
NBIX icon

Asset Management One’s Neurocrine Biosciences NBIX Stock Holding History

Asset Management One’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.41M Sell
41,060
-3,148
-7% -$418K 0.02% 579
2025
Q4 		$6.35M Buy
44,208
+3,336
+8% +$483K 0.02% 569
2025
Q3 		$5.74M Buy
40,872
+311
+0.8% +$42.1K 0.02% 587
2025
Q2 		$5.1M Sell
40,561
-26,624
-40% -$3.05M 0.02% 601
2025
Q1 		$7.43M Sell
67,185
-3,246
-5% -$411K 0.03% 499
2024
Q4 		$9.82M Buy
70,431
+1,201
+2% +$149K 0.03% 437
2024
Q3 		$7.98M Buy
69,230
+1,705
+3% +$234K 0.03% 485
2024
Q2 		$9.3M Buy
67,525
+30,096
+80% +$4.13M 0.04% 427
2024
Q1 		$5.16M Buy
37,429
+246
+0.7% +$33.6K 0.02% 588
2023
Q4 		$4.91M Sell
37,183
-1,479
-4% -$170K 0.02% 599
2023
Q3 		$4.35M Buy
38,662
+207
+0.5% +$21.8K 0.02% 613
2023
Q2 		$3.63M Buy
38,455
+2,380
+7% +$233K 0.02% 674
2023
Q1 		$3.65M Buy
36,075
+148
+0.4% +$15.4K 0.02% 661
2022
Q4 		$4.32M Sell
35,927
-2,102
-6% -$246K 0.02% 602
2022
Q3 		$4.04M Buy
38,029
+58
+0.2% +$5.88K 0.02% 614
2022
Q2 		$3.7M Sell
37,971
-2
-0% -$185 0.02% 658
2022
Q1 		$3.56M Sell
37,973
-640
-2% -$54.2K 0.01% 705
2021
Q4 		$3.25M Sell
38,613
-602
-2% -$55.4K 0.01% 759
2021
Q3 		$3.76M Buy
39,215
+166
+0.4% +$15.7K 0.01% 732
2021
Q2 		$3.8M Sell
39,049
-1,045
-3% -$100K 0.01% 738
2021
Q1 		$3.9M Sell
40,094
-3,135
-7% -$329K 0.02% 713
2020
Q4 		$4.07M Sell
43,229
-8,090
-16% -$781K 0.02% 689
2020
Q3 		$4.94M Sell
51,319
-339
-0.7% -$39.2K 0.02% 590
2020
Q2 		$6.3M Buy
51,658
+8,569
+20% +$947K 0.03% 500
2020
Q1 		$3.73M Sell
43,089
-15,270
-26% -$1.49M 0.02% 579
2019
Q4 		$6.27M Buy
58,359
+42,389
+265% +$4.44M 0.03% 548
2019
Q3 		$1.44M Hold
15,970
– – 0.01% 829
2019
Q2 		$1.35M Buy
15,970
+5,419
+51% +$445K 0.01% 851
2019
Q1 		$930K Buy
+10,551
New +$882K 0.01% 882
2017
Q1 		– Sell
-5,163
Closed -$197K – 1044
2016
Q4 		$197K Sell
5,163
-147,554
-97% -$6.68M ﹤0.01% 918
2016
Q3 		$7.69M Sell
152,717
-17,650
-10% -$879K 0.11% 201
2016
Q2 		$7.73M Sell
170,367
-13,481
-7% -$621K 0.12% 195
2016
Q1 		$6.83M Buy
183,848
+30,349
+20% +$1.2M 0.1% 221
2015
Q4 		$8.67M Buy
153,499
+10,250
+7% +$521K 0.13% 185
2015
Q3 		$5.13M Sell
143,249
-57,621
-29% -$2.79M 0.08% 315
2015
Q2 		$9.2M Buy
200,870
+7,277
+4% +$309K 0.13% 204
2015
Q1 		$8.04M Sell
193,593
-28,094
-13% -$1M 0.1% 261
2014
Q4 		$4.96M Buy
221,687
+66,890
+43% +$1.27M 0.06% 385
2014
Q3 		$2.49M Buy
+154,797
New +$2.31M 0.03% 543

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Asset Management One's NBIX Position: Q1 2026 in Review

Asset Management One reduced its Neurocrine Biosciences (NBIX) stake by 7.1% in Q1 2026, selling an estimated $418K and leaving 41,060 shares worth $5.41M. The position accounts for 0.02% of the portfolio, ranked #579.

Asset Management One first reported a position in NBIX in Q3 2014 and has held it in 39 quarters since. The position peaked at $9.82M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Asset Management One held 41,060 shares of Neurocrine Biosciences worth $5.41M as of Q1 2026.
  • Asset Management One sold 3,148 Neurocrine Biosciences shares in Q1 2026, an estimated $418K.
  • Neurocrine Biosciences made up 0.02% of Asset Management One's portfolio in Q1 2026, its #579 holding.
  • Asset Management One first reported a position in Neurocrine Biosciences in Q3 2014 and has held it in 39 quarters since.
  • Asset Management One's Neurocrine Biosciences position peaked at $9.82M in Q4 2024.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Asset Management One's 13F filing for Q1 2026, filed 8 May 2026.